<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20161218031450N7</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-26</date_registration>
      <primary_sponsor>Research Assistant of Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>comparison of clinical outcomes of phacoemulsification combined with deep sclerectomy versus phacoemulsification combined with trabeculectomy in patients with primary angle closure glaucoma, A randomized controlled clinical trial</public_title>
      <acronym></acronym>
      <scientific_title>comparison of clinical outcomes of phacoemulsification combined with deep sclerectomy versus phacoemulsification combined with trabeculectomy in patients with primary angle closure glaucoma, A randomized controlled clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-02-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/75266</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Using computer software (Random Allocation Software), the subjects were divided into two intervention groups through four and six blocks with an allocation ratio of 1:1 in two intervention groups (cataract combined with deep sclerectomy) or control (cataract combined with trabeculectomy) are placed. The random sequence of allocation will be produced by a person not involved in the research. And the researcher will not know about the random grouping of patients, Blinding description: In this study, patients will be divided into two groups based on the randomization form. The patient will not know the type of surgery that will be performed. Also, the researcher who collects the data of the study will not know what was done on the patient.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Gluocoma.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Deep sclerectomy surgery with cataract .In this group of patients, a surgeon with a glaucoma fellowship undergoes phacoemulsification surgery for the patient's cataract, and deep sclerectomy is performed through scleral incisions in the patient's limbus area and the adjacent conjunctiva to increase the drainage of the aqueous humor. Intervention 2: The second intervention group: combined cataract surgery with trabeculectomy.In this group of patients, a surgeon with a glaucoma fellowship undergoes phacoemulsification surgery for the patient's cataract, and trabeculectomy is performed through incisions in the limbus area of ​​the patient and the adjacent conjunctiva with access to the space of the trabecular meshwork to increase the drainage of the aqueous humor.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All necessary and collected data and information will be provided as data

When:
Beginning of the access period from 1404

To whom:
Professors and colleagues and universities of medical sciences in the field of ophthalmology

Conditions:
The data will be usable for ophthalmology specialists for use in the ophthalmology clinic and treatment of patients.

Where to obtain:
Tabriz University of Medical Sciences, Department of Ophthalmology

How to obtain:
After completing the study, the information will be published in the form of an article.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Farhad Najafzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Abbasi St. in front of police force number 12</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5154645395</zip>
        <telephone>+98 41 3657 7336</telephone>
        <email>miladsheikhian007@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Ali Moustafaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Abbasi St., in front of police force number 12, Nikoukari Ophthalmological Hospital</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5154645395</zip>
        <telephone>+98 41 3657 7336</telephone>
        <email>miladsheikhian007@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Significant cataract with PACG (a closed angle on gonioscopy for at least 180 degrees of angle)
Uncontrolled IOP despite maximal tolerable medication
Controlled glaucoma with multiple eye drops  and progression of disease in the visual fields</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Open angle glaucoma
Secondary angle closure glaucoma: NVG, uveitic glaucoma
PACG with 360-degree PAS or having PAS at the site of DS surgery (superior)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H40</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Glaucoma</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Deep sclerectomy surgery with cataract .In this group of patients, a surgeon with a glaucoma fellowship undergoes phacoemulsification surgery for the patient's cataract, and deep sclerectomy is performed through scleral incisions in the patient's limbus area and the adjacent conjunctiva to increase the drainage of the aqueous humor.</i_keyword>
      <i_keyword>The second intervention group: combined cataract surgery with trabeculectomy.In this group of patients, a surgeon with a glaucoma fellowship undergoes phacoemulsification surgery for the patient's cataract, and trabeculectomy is performed through incisions in the limbus area of ​​the patient and the adjacent conjunctiva with access to the space of the trabecular meshwork to increase the drainage of the aqueous humor.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Intraocular pressure. Timepoint: The first week, the first month, the third month, the sixth month and the twelfth month after the operation. Method of measurement: Using a slate lamp and a Goldman tonometer.</prim_outcome>
      <prim_outcome>The patient's vision. Timepoint: Months 1, 3, 6, 12 after the operation. Method of measurement: Using the Snellen chart.</prim_outcome>
      <prim_outcome>Peripheral visual field. Timepoint: 6 and 12 months after the operation. Method of measurement: Using perimeter.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Research Assistant of Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-12-18</approval_date>
        <contact_name>Ethics Committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Abbasi St. in front of police force number 12 Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
